Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Original Paper
  • Published:

Absence of PPP2R1B gene alterations in primary ovarian cancers

Oncogene volume 18, pages 6367–6369 (1999)Cite this article

Abstract

The PPP2R1B gene has recently been implicated as a tumor suppressor based on the finding of somatic alterations in lung and colon cancers. PPP2R1B is located on chromosome 11q22 – 24 which coincides with the site of frequent loss of heterozygosity (LOH) in ovarian cancer. We investigated if the PPP2R1B gene was inactivated in ovarian cancer by single strand conformational polymorphism (SSCP) and heteroduplex (HD) analysis of 99% of the coding region. LOH at the PPP2R1B locus was detected in 32% of the malignant tumors but no somatic alterations were detected in any of 65 malignant, five borderline or six benign tumors. A germline G>A transition (GGC>GAC) in codon 90 was detected in 4/76 tumors. This alteration has previously been described as a mutation but on further investigation we found that the frequency of this variant among 167 ovarian cancers (4.2%) was not statistically significantly different from that observed in 247 non-cancer random controls (2.4%). We conclude that the PPP2R1B gene is not involved in the pathogenesis of ovarian cancer. The codon 90 Gly>Asp alteration may represent a non-pathological polymorphism and consequently the mutation frequency reported in lung cancers may have been overstated and the designation of PPP2R1B as a tumor suppressor gene should be regarded with caution.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Figure 1

Similar content being viewed by others

References

  • Baysal BE, Farr JE, Goss JR, Devlin B and Richard CW. . 1998 Gene 217: 107–116.

  • Campbell IG, Nicolai HM, Foulkes WD, Senger G, Stamp GW, Allan, G, Boyer C, Jones K, Bast RC, Solomon E, Trowsdale J and Black DM. . 1994 Hum. Mol. Genet. 3: 589–594.

  • Davis M, Hitchcock A, Foulkes WD and Campbell IG. . 1996 Cancer Res. 56: 741–744.

  • Evans MF, Koreth J, Bakkenist CJ, Herrington CS and McGee JOD. . 1998 Oncogene 16: 2557–2564.

  • Gabra H, Watson JE, Taylor KJ, Mackay J, Leonard RC, Steel CM, Porteous DJ and Smyth JF. . 1996 Cancer Res. 56: 950–954.

  • Gayther SA, Barski P, Batley SJ, Li LM, de Foy KAF et al. 1997 Oncogene 15: 2119–2126.

  • Herbst RA, Gutzmer R, Matiaske F, Mommert S, Gasper U, Kappa A and Weiss J. . 1999 Int. J. Cancer 80: 205–209.

  • Hui ABY, Lo KW, Leung SF, Choi PHK, Fong Y, Lee JCK and Huang D. . 1996 Cancer Res. 56: 3225–3229.

  • Koreth J, Bakkenist CJ and McGee JOD. . 1997 Oncogene 14: 431–437.

  • Monaco C, Negrini M, Sozzi G, Veronese ML, Vorechovsky I, Godwin AK and Croce CM. . 1997 Genomics 46: 217–222.

  • Monaco C, Citterich MH, Caprini E, Vorechovsky I, Russo G, Croce CM, Barbanti-Brodano G and Negrini M. . 1998 Genomics 52: 358–362.

  • Murakami Y, Nobukuni T, Tamura K, Maruyama T, Sekiya T et al. 1998 Proc. Natl. Acad. Sci. USA 95: 8153–8158.

  • Obata K, Morland SJ, Watson RH, Hitchcock A, Chenevix-Trench G et al. 1998 Cancer Res. 58: 2095–2097.

  • Skomedal H, Kristensen GB, Abeler VM, Borresen-Dale AL, Trope C and Holm R. . 1997 J. Pathol. 181: 158–165.

  • Wang L, Darling J, Zhang JS, Qian CP, Hartmann L, Conover C, Jenkins R and Smith DI. . 1998a Oncogene 16: 635–642.

  • Wang SS, Esplin ED, Li JL, Huang LY, Gazdar A, Minna J and Evans GA. . 1998b Science 282: 284–287.

Download references

Acknowledgements

T Manolitsas was a recipient of the Fotheringham Fellowship from the Royal College of Obstetricians and Gynaecologists. This work was also supported in part by grants from the Wessex Cancer Trust, The Wessex Medical Trust and The Association for International Cancer Research.

Author information

Authors and Affiliations

  1. Department of Obstetrics and Gynaecology, University of Southampton, Princess Anne Hospital, Coxford Road, Southampton, SO16 5YA, UK

    I G Campbell & T Manolitsas

  2. Peter MacCallum Cancer Institute, St Andrews Place, East Melbourne, 3002, Victoria, Australia

    I G Campbell

Authors
  1. I G Campbell
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. T Manolitsas
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Campbell, I., Manolitsas, T. Absence of PPP2R1B gene alterations in primary ovarian cancers. Oncogene 18, 6367–6369 (1999). https://doi.org/10.1038/sj.onc.1203070

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/sj.onc.1203070

Keywords

This article is cited by

Search

Advanced search

Quick links